(Circulation. 1995;92:3194-3200.)
© 1995 American Heart Association, Inc.
Articles |
Effect of Thromboxane A2 Blockade on Clinical Outcome and Restenosis After Successful Coronary Angioplasty
Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
From the Multi-Hospital Eastern Atlantic Restenosis Trialists (study chairman, Carl J. Pepine, MD). The participating sites and investigators are listed in the "Appendix."
Correspondence to Michael Savage, MD, Cardiac Catheterization Suite, 5360 Gibbon Building, Thomas Jefferson University Hospital, 111 S 11th St, Philadelphia, PA 19107.
Background Antithromboxane therapy with aspirin reduces acute procedural complications of coronary angioplasty (PTCA) but has not been shown to prevent restenosis. The effect of chronic aspirin therapy on long-term clinical events after PTCA is unknown, and the utility of more specific antithromboxane agents is uncertain. The goal of this study was to assess the effects of aspirin (a nonselective inhibitor of thromboxane A2 synthesis) and sulotroban (a selective blocker of the thromboxane A2 receptor) on late clinical events and restenosis after PTCA.
Methods and Results Patients (n=752) were randomly assigned to aspirin (325 mg daily), sulotroban (800 mg QID), or placebo, started within 6 hours before PTCA and continued for 6 months. The primary outcome was clinical failure at 6 months after successful PTCA, defined as (1) death, (2) myocardial infarction, or (3) restenosis associated with recurrent angina or need for repeat revascularization. Neither active treatment differed significantly from placebo in the rate of angiographic restenosis: 39% (73 of 188) in the aspirin-assigned group, 53% (100 of 189) in the sulotroban group, and 43% (85 of 196) in the placebo group. In contrast, aspirin therapy significantly improved clinical outcome in comparison to placebo (P=.046) and sulotroban (P=.006). Clinical failure occurred in 30% (49 of 162) of the aspirin group, 44% (73 of 166) of the sulotroban group, and 41% (71 of 175) of the placebo group. Myocardial infarction was significantly reduced by antithromboxane therapy: 1.2% in the aspirin group, 1.8% in the sulotroban group, and 5.7% in the placebo group (P=.030).
Conclusions Thromboxane A2 blockade protects against late ischemic events after angioplasty even though angiographic restenosis is not significantly reduced. While both aspirin and sulotroban prevent the occurrence of myocardial infarction, overall clinical outcome appears superior for aspirin compared with sulotroban. Therefore, aspirin should be continued for at least 6 months after coronary angioplasty.
Key Words: angioplasty • myocardial infarction • aspirin • platelets • restenosis
This article has been cited by other articles:
 |
|
 |
|
  S. M. King, R. A. McNamee, A. K. Houng, R. Patel, M. Brands, and G. L. Reed Platelet Dense-Granule Secretion Plays a Critical Role in Thrombosis and Subsequent Vascular Remodeling in Atherosclerotic Mice Circulation, September 1, 2009; 120(9): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl and P. B. Berger Aspirin following PCI: too much of a good thing? Eur. Heart J., April 2, 2009; 30(8): 882 - 884. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott and E. M. Antman Clopidogrel Resistance: A New Chapter in a Fast-Moving Story Circulation, June 29, 2004; 109(25): 3064 - 3067. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Chan, D. J. Moliterno, P. B. Berger, G. W. Stone, P. M. DiBattiste, S. L. Yakubov, S. K. Sapp, K. Wolski, D. L. Bhatt, E. J. Topol, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival: Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET) J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1188 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Smith, T. A. Alshafie, C. P. Cruz, C.-Y. Fan, A. T. Brown, Y. Wang, J. F. Eidt, and M. M. Moursi Saratin, an Inhibitor of Collagen-Platelet Interaction, Decreases Venous Anastomotic Intimal Hyperplasia in a Canine Dialysis Access Model Vascular and Endovascular Surgery, July 1, 2003; 37(4): 259 - 269. [Abstract] [PDF]
|
|
|
|
 |
|
 T. E. Van Dyke and C.N. Serhan Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases Journal of Dental Research, February 1, 2003; 82(2): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kantarci and T. E. Van Dyke LIPOXINS IN CHRONIC INFLAMMATION Critical Reviews in Oral Biology & Medicine, January 1, 2003; 14(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cheng, S. C. Austin, B. Rocca, B. H. Koller, T. M. Coffman, T. Grosser, J. A. Lawson, and G. A. FitzGerald Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 Science, April 19, 2002; 296(5567): 539 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pratico, Y. Cheng, and G. A. FitzGerald TP or Not TP: Primary Mediators in a Close Runoff? Arterioscler Thromb Vasc Biol, July 1, 2000; 20(7): 1695 - 1698. [Full Text] [PDF]
|
|
|
|
|
|
L. P. Audoly, B. Rocca, J.-E. Fabre, B. H. Koller, D. Thomas, A. L. Loeb, T. M. Coffman, and G. A. FitzGerald Cardiovascular Responses to the Isoprostanes iPF2{alpha}-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo Circulation, June 20, 2000; 101(24): 2833 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. SERHAN, T. TAKANO, N. CHIANG, K. GRONERT, and C. B. CLISH Formation of Endogenous ""Antiinflammatory"" Lipid Mediators by Transcellular Biosynthesis . Lipoxins and Aspirin-triggered Lipoxins Inhibit Neutrophil Recruitment and Vascular Permeability Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S95 - 101. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Azar, R. G. McKay, P. D. Thompson, J. A. Hirst, J. F. Mitchell, D. B. Fram, D. D. Waters, and F. J. Kiernan Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chiang, T. Takano, C. B. Clish, N. A. Petasis, H.-H. Tai, and C. N. Serhan Aspirin-Triggered 15-epi-Lipoxin A4 (ATL) Generation by Human Leukocytes and Murine Peritonitis Exudates: Development of a Specific 15-epi-LXA4 ELISA J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 779 - 790. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]
|
|
|
|
|
|
T.-Ph. Zucker, D. Bonisch, S. Muck, A.-A. Weber, E. Bretschneider, E. Glusa, and K. Schror Thrombin-Induced Mitogenesis in Coronary Artery Smooth Muscle Cells Is Potentiated by Thromboxane A2 and Involves Upregulation of Thromboxane Receptor mRNA Circulation, February 17, 1998; 97(6): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]
|
|
|
|
 |
|
 D. L. Fischman and M. P. Savage The Platelet, the Patient, and Periprocedural Infarction During Percutaneous Transluminal Coronary Angioplasty JAMA, August 13, 1997; 278(6): 518 - 519. [Abstract] [PDF]
|
|